The Carlyle Group and Hellman & Friedman have completed their $3.9 billion acquisition of PPD (NYSE:PPDI). The private equity firms announced the completion of the all-cash deal for the clinical research organization today. The close follows an approval vote from shareholders last week. At the Nov. 30 shareholders meeting at PPD’s Wilmington, North Carolina headquarters, […]
PPD (NYSE:PPDI), among the largest clinical research organizations in the industry, is on its way to becoming a private company. Shareholders voted to approve the $3.9 billion sale of the Wilmington, North Carolina-based CRO to private equity firms The Carlyle Group and Hellman & Friedman. PPD said that more than 96 percent of shares voting […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Any PPD (NYSE:PPDI) shareholders with something to say about the $3.9 billion sale of the clinical research organization will probably be making their way today to the coastal city of Wilmington, North Carolina. At PPD’s global headquarters, the CRO has scheduled a meeting for shareholders to vote whether to approve the sale to private equity […]
PPD (NYSE:PPDI) will have no other acquirers trying to top the $3.9 billion bid for the clinical research organization from private equity firms The Carlyle Group and Hellman & Friedman. Just one party entered into the same confidentiality agreements that Carlyle and H&F agreed to in order to begin acquisition talks with the CRO. But […]
Days before PPD‘s (NYSE:PPDI) $3.9 billion sale to private equity was announced on October 3, the clinical research organization’s lead independent director, Ernest Mario, was busy trading e-mails and phone calls with The Carlyle Group in an effort to improve what had become a substantially reduced offer. Carlyle and Hellman & Friedman, the other private […]
PPD‘s (NYSE:PPDI) $3.9 billion sale to The Carlyle Group and Hellman & Friedman offered shareholders of the clinical research organization a nearly 30 percent premium over the company’s closing stock price before the private equity deal was announced. But www.footnoted.com, a unit of Morningstar that looks for hidden items buried in securities filings, suggested that […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
PPD‘s (NYSE:PPDI) founder and former CEO Fred Eshelman launched Pharmaceutical Product Development out of his Maryland home in 1985. Twenty six years later, the company Eshelman started as a one-man consultancy is set to be sold for just shy of $4 billion. Wilmington, North Carolina clinical research organization PPD announced today private equity firms The […]
PPD‘s (NYSE:PPDI) $3.9 billion acquisition by private equity firms The Carlyle Group and Hellman & Friedman is just the latest in a growing string of private equity deals involving clinical research organizations. Activity in the CRO space is being driven by its growth: the CRO business has grown and is projected to grow even more […]
North Carolina clinical research organization PPD (NYSE:PPDI) will be acquired by two private equity firms in a $3.9 billion cash deal that will take the CRO private. PPD announced the definitive merger agreement with The Carlyle Group and Hellman & Friedman Monday. The sale price comes to $33.25 per share, a 29.6 percent premium over […]
PPD‘s (NYSE:PPDI) new CEO Ray Hill doesn’t come from a clinical research organization, but his experience fits with where the CRO industry is going. IMS Health provides data and research for pharmaceutical companies and others in the health space. As a provider of research and services to pharma companies, IMS’ work is not far off […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
PPD‘s (NYSE:PPDI) new CEO brings the clinical research organization a long track record in healthcare and life sciences consulting. Raymond Hill comes to Wilmington, North Carolina-based PPD from research and consulting firm IMS Health, where he has worked for the past eight years. His appointment as PPD CEO and member of the CRO’s board of […]
Clinical research organization PPD (NYSE:PPDI) has appointed a chief scientific officer for BioDuro, its drug discovery subsidiary in China. Jasmine Cui brings to PPD more than 15 years of drug discovery experience, including 14 years at Merck (NYSE:MRK). Wilmington, North Carolina-based PPD has made China a big part of its business through acquisitions. In 2009, […]
Clinical research organization PPD (NYSE:PPDI) is talking with private equity firm The Carlyle Group about an M&A deal. Bloomberg News reports that Carlyle is in exclusive talks to possibly acquire Wilmington, North Carolina-based PPD, which is the third-largest CRO in the industry with more than $1.4 billion in 2010 revenue. Bloomberg cited five unnamed sources […]
PPD (NYSE:PPDI) released second-quarter earnings today and in the conference call to follow Wednesday morning, I would bet on at least two questions analysts will pose to management of the North Carolina clinical research organization: How is the search progressing for a new CEO to replace retired CEO David Grange? Is PPD in talks with […]
Talk of whether PPD (NYSE:PPDI) is for sale has prompted the clinical research organization to publicly state it not in talks with any other CRO regarding a merger or acquisition. But Wilmington, North Carolina-based PPD did say that its board of directors has asked management to review the company’s strategic plan and capital structure “with […]